MyMD Pharmaceuticals Inc (MYMD)

[leifsmith]

Sometimes stock price is based on incomplete information.

Take a look at what happened to Tempest Pharmaceuticals (TPST) on 11 Oct 2023.

Information previously unknown to market participants became known. On that day the stock opened at $0.17, moved up on wild speculation to $9.80, and closed at $3.60. Its current price is $3.76.

A stock chart will show a pattern of steady decline that resembles what we are seeing for MYMD.

But, nothing about TPST can be taken to predict anything about the future of MYMD.

TPST does illustrate that sudden introduction of new information can have a radical effect on stock price.

Such may happen with MYMD. My understanding of the science suggests to me that it's possible. Ray may have his day.

[leifsmith]

Sometimes stock price is based on incomplete information.

Take a look at what happened to Tempest Pharmaceuticals (TPST) on 11 Oct 2023.

Information previously unknown to market participants became known. On that day the stock opened at $0.17, moved up on wild speculation to $9.80, and closed at $3.60. Its current price is $3.76.

A stock chart will show a pattern of steady decline that resembles what we are seeing for MYMD.

But, nothing about TPST can be taken to predict anything about the future of MYMD.

TPST does illustrate that sudden introduction of new information can have a radical effect on stock price.

Such may happen with MYMD. My understanding of the science suggests to me that it's possible.

Ray Blanco may have his day.

[Regis999]

Business Strategy ? How about judging such based upon the market price?

[leifsmith]

Ray Blanco is correct about the science. Credible results from trials can make that clear, and I think they will do that. However, the quality of business strategy is not something I can judge.

[Regis999]

The 2023 Turkey of the Year award goes…
Frank Curio and Ray Blanco touting MyMD Pharmaceuticals (MYMD), and a couple folks pitching Plug Power (PLUG) weren’t very far behind.

[Regis999]

New 52 Week Low--huge selling volume

[leifsmith]

Last trade of the day: 1,387,425 shares.

[leifsmith]

The link you posted leads to something good - not obvious from the url only:

"Revolutionizing Autoimmune Medicine: MyMD Pharmaceuticals Innovative Therapies
BioTalk with Rich Bendis"

https://podcasts.apple.com/us/podcast/revolutionizing-autoimmune-medicine-mymd-pharmaceuticals/id1274273731

Thanks!

[B and B]

Great podcast https://apple.co/46wCAsf

[B and B]

Great podcast https://apple.co/46wCAsf

[leifsmith]

News Release Today

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

https://ir.mymd.com/news-events/press-releases/detail/54/mymd-announces-preclinical-study-results-showing-novel

[saxonia40271]

Public companies generally can’t drop bombshells in private settings. A common solution is to distribute the information to the public on the same day, preferably before the presentation. Without such a document, you can assume that they revealed nothing new.

[Regis999]

Call Investors:
Robert Schatz
[phone]
[e-mail]

[deast]

Does anyone know what Chapman said in his presentation at the Bio Future 2023? Maybe it's a closely guarded secret.

[Monksdream]

MYMD new 52 week low

[leifsmith]

PR: new data on Potential TNF-a Market Disrupter

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023

https://www.businesswire.com/news/home/20231004139695/en/

[Monksdream]

MYMD new 52 week low

[Regis999]

The sad part of all this Anatabloc was by itself a great product. IMHO just having Williams involved tainted it and doomed it for failure.

Just look under the hood of MYMD. IMHO a facade of deception. Why follow the same script?

[SeanVan]

The newsweek magazine published 9 years ago about the fraudulent Founder of MyMD Pharma Jonnie Williams , and previous founder of failed companies : Star Scientific & Rockcreek pharma.
Every one must read this article.. He is called as penny stock hoader... repeating same after 15 years..
https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html

[Monksdream]

MYMD new 52 week low

[Monksdream]

MYMD new 52 week low

[Regis999]

Same story all the time. You would think they would learn something from the past. Smoke and Mirrors.

[Monksdream]

MYMD new 52 week low

[SeanVan]

Sounds a fraudulent company, these same folks failed and manipulated same "small molecule( Pre version of MyMD-1 as Anatabloc)" using Star scientific and Rockcreek pharma and looted common man money.. Very dangerous manipulation by owner: Jonnie Williams. There might be a class action suit by investors soon.

[B and B]

MyMD looking to go back to the future with oral TNF blocker

Based on what the company has seen in preclinical models, Chapman believes they may have a “pipeline in a pill” on their hands in MYMD-1, which has demonstrated efficacy in a host of conditions. The lead indication was determined to be sarcopenia, or age-related frailty, “which is a significant unmet need with no treatments currently approved,” he remarked

Chapman told FirstWord that he is hoping for feedback on whether an accelerated approval path for MYMD-1 may be on the table for sarcopenia given the lack of alternatives. The company will be ready to move into one or more studies sometime in the next few months, and he said they have already begun fielding calls from prospective partners who may be interested in getting involved.

#MyMD #TNFBlocker #OralTreatment #MYMD1 #Sarcopenia #ImmuneMediatedDiseases #Inflammation #RheumatoidArthritis #DrugDevelopment #HealthcareResearch #clinicaltrials

https://firstwordpharma.com

[B and B]

MyMD looking to go back to the future with oral TNF blocker

Based on what the company has seen in preclinical models, Chapman believes they may have a “pipeline in a pill” on their hands in MYMD-1, which has demonstrated efficacy in a host of conditions. The lead indication was determined to be sarcopenia, or age-related frailty, “which is a significant unmet need with no treatments currently approved,” he remarked

Chapman told FirstWord that he is hoping for feedback on whether an accelerated approval path for MYMD-1 may be on the table for sarcopenia given the lack of alternatives. The company will be ready to move into one or more studies sometime in the next few months, and he said they have already begun fielding calls from prospective partners who may be interested in getting involved.

#MyMD #TNFBlocker #OralTreatment #MYMD1 #Sarcopenia #ImmuneMediatedDiseases #Inflammation #RheumatoidArthritis #DrugDevelopment #HealthcareResearch #clinicaltrials

https://firstwordpharma.com

[B and B]

https://www.clinicaltrialsarena.com/news/mymd-rheumatoid-arthritis/

[SeanVan]

Pickvitamin.com is selling....
.
https://pickvitamin.com/hydrapharm-formulas-anatabloc-150-capsules.html

[sheepsandgoats]

Promising day goes south as shorts buy into their cycle positions (sell to open). Unfortunately for them, this is not a typical cycle (as long as longs don't cave). Pitch man better bolster his investment community.

[deast]

PickVitamin, Arcadia, CA ,909-999-2026

[B and B]

Anyone still selling Anatabloc??

[leifsmith]

PR This morning: Positive Sarcopenia Results

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-a Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

https://www.benzinga.com/pressreleases/23/07/b33469123/mymd-pharmaceuticals-reports-statistically-significant-positive-topline-phase-2-results-for-next-g

Hi Ray Blanco - expecting to hear from you!

[trading halted until 9:50 am]

[B and B]

Where the massive naked short selling is coming from- Google and read- The Trillion Dollar Naked Short Selling Scam: Is Europe Destroying American Companies?

[deast]

Mira Pharmaceuticals IPO $7 million?

[deast]

Hopefully, Williams gets it right this time.

[Regis999]

So many unknowns with Williams running the show.

[Monksdream]

MYMD new 52 week low

[sheepsandgoats]

Most likely a pre-emptive filing due to risk of being de-listed for failing to maintain Nasdaq requirements.

[leifsmith]

SEC filing today: "MyMD Pharmaceuticals Inc Awaits Receipt Of Data From Phase 2 Trial For MYMD-1"

This was in an SEC filing, an 8-K, from the company, today. The above is the entire content of the filing.

https://content.equisolve.net/sec/0001493152-23-024537/form8-k.htm

Why would they put out such a statement?

[leifsmith]

Will buy more. I think Blanco gets it right.

[bhodi]

Leif, what are ur thoughts on the sell off and price action. Blanco seems very confident with Mymd

[leifsmith]

You are right.

[B and B]

Could not agree more you are spot on. Holding/waiting w a very large position. The massive legal and naked short will find out soon enough what this company has been up too. The complete opposite of a pump and dump (we hear nothing from the company) making me even more excited for phase 2 results

[BioFan1]

OK, folks, not sure how many follow this board or care, but I do want the pleasure of saying "I told you so" next year. What the hell is sarcopenia, you ask, and why make a drug for it? Here's a headline from 2017:

The CDC recently recognized sarcopenia as a reportable medical condition necessitating better screening and diagnosis of this geriatric syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576154/

CDC recognition means the treatment can now be medically diagnosed, treated and, most importantly, billed! And it has its very own ICD-10 billing code. Sarcopenia article

Excerpt from the article: "Recently, there has been a call to action to systematically address sarcopenia by interdisciplinary organizations such as the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Working Group on Sarcopenia (IWGS).4,5 This call to action is due to the association of sarcopenia with increased health care costs, higher disability incidence, and elevated risk of mortality.6,7 The consequences of sarcopenia may include serious complications, such as hip fracture or a loss of functional independence. 8,9 The CDC now recognizes sarcopenia as an independently reportable medical condition. Consequently, physicians, nurse practitioners (NPs), and other associated health professionals within the VA will need to better understand clinically viable and valid methods to screen and diagnose this geriatric syndrome."

As of today, there are NO approved drugs for this newly recognized condition that affects millions. So, MYMD-1 will launch as the only FDA-approved drug that physicians can prescribe for this condition. And it happens to be safe, with none of the toxicity in other TNF alpha blockers that no doctor in his right mind would prescribe for sarcopenia. In other words, a virtual monopoly on treatment of this widespread condition. Not to mention the other indications to follow, like arthritis, MS, and other inflammatory diseases.

MYMD is on sale these days, like a lot a biotech startups. You can thank me later.

[deast]

Absolutely!

[leifsmith]

I don't see an ethical problem. Incentives matter. I like companies where the people who make me wealthier have a chance to do the same for themselves.

The options cost nothing and are exercisable in five years at a stated price ($1.66).

See Table II, Column 8, where "Price of Derivative Security" is listed as $0. And the "Conversion" (exercise) price, shown in column 2 will be, five years from 06/07/23, $1.66.

If they exercise the options at that price when the stock is selling at a much higher price they will make money and they will have made money for us. Fair, as I see it.

[BioFan1]

The studies demonstrate that MYMD-1 is a highly effective blocker of TNF-a. https://www.mymd.com/news/recap-of-mymd-pharmaceuticals-inc-recent-publications-and-presentations Virtually every drug commercial on television these days is about some form of TNA-a blocker, but with horrific side effects and warnings about multitude of ways the drugs can damage or kill you (all to happy music and smiling people). The home run potential of this stock once MYMD-1 clears Phase 2 is unlimited. This is why investors like Ray Dalio are in the stock.

[SeanVan]

Yes. The insiders/Board right to buy option at a very low price $1.60 /acquired over 2.5 Million shares last week. Too much manipulation is going on in this smallest company. So far they proved legally correct but pure unethical practices.

[deast]

Several insiders filed Form 4 with the SEChttps://stocktwits.com/Quantisnow/message/531508790 on June 9, 2023.

[Twice Worthy]

Dosing completed with Sarcopenia cohorts in the blinded study of MYMD-1 drug. FDA's Safety Committee will be reviewing the results of the blinded study. The results will be shared with MYMD once completed and, the company would then post the results from the study. The results from the study could be very significant and could begin to propel MYMD stock higher based on the new drug's effect with patients. The study results should be posted in a few weeks ... very much looking forward to them and the effect on MYMD's share price.